CN114344186A - 色素稳定剂 - Google Patents
色素稳定剂 Download PDFInfo
- Publication number
- CN114344186A CN114344186A CN202111199733.9A CN202111199733A CN114344186A CN 114344186 A CN114344186 A CN 114344186A CN 202111199733 A CN202111199733 A CN 202111199733A CN 114344186 A CN114344186 A CN 114344186A
- Authority
- CN
- China
- Prior art keywords
- pigment
- extract
- stabilizer according
- pigment stabilizer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000049 pigment Substances 0.000 title claims description 47
- 239000003381 stabilizer Substances 0.000 title claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 28
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 claims abstract description 15
- 229940033280 alpha-arbutin Drugs 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 16
- 244000139693 Arctostaphylos uva ursi Species 0.000 claims description 9
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 241000228212 Aspergillus Species 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 3
- 241000555678 Citrus unshiu Species 0.000 claims description 3
- 229920002230 Pectic acid Polymers 0.000 claims description 3
- 244000302661 Phyllostachys pubescens Species 0.000 claims description 3
- 235000003570 Phyllostachys pubescens Nutrition 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 3
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims description 3
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 claims description 3
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 241001647902 Arctostaphylos Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000004472 Lysine Substances 0.000 abstract description 8
- 206010040829 Skin discolouration Diseases 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 206010040865 Skin hyperpigmentation Diseases 0.000 abstract description 2
- -1 p-nitrophenyl ester Chemical class 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000031019 skin pigmentation disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100422515 Mus musculus Stk32c gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 240000000147 Torreya grandis Species 0.000 description 1
- 235000016410 Torreya grandis Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- ZYIPABRMGYNQKB-UHFFFAOYSA-N benzyl n-(5-phenyl-1,3-oxazol-2-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(O1)=NC=C1C1=CC=CC=C1 ZYIPABRMGYNQKB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010065320 prolyl-lysyl-glutamyl-lysine Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供用于皮肤美白的药物组合物及其使用方法，所述药物组合物特别适用于治疗皮肤色素沉着过度。所述组合物包含肽、α熊果苷和/或舒替兰酶，所述肽具有包含脯氨酸‑赖氨酸‑谷氨酸‑赖氨酸的序列。
Description
相关申请的交叉参考
无。
并入序列表
此文件通过引用在本文中并入电子序列表文本档案，所述电子序列表文本档案通过EFS网络以电子格式与本申请一起提交。所述文本档案名为“35-20_US_Seq_listing_ST25.txt”，为340字节，且创建于2020年10月14日。
背景技术
老年斑、光损伤、黄褐斑、炎症、痤疮疤痕及其他环境损伤及生理状况都会导致皮肤色素异常。这些异常通常是由于黑色素的过度产生，其导致真皮受影响的区域变得比周围组织更暗。而且，令人惊讶的是，用于解决不均匀着色的皮肤激光治疗常常会在短时间内增加问题区域的炎症、发红及色素沉着过度。
对于患有皮肤色素异常的人来说，减少变暗区域的出现并使受影响区域与周围组织融合所需的时间长度非常重要。不幸的是，大多数承诺快速见效的局部制剂(topicalformulation)即使有作用也只能缓慢地发挥作用使皮肤恢复到其原来的色素沉着。
发明内容
本文中公开的组合物及方法包含组合物，所述组合物包含：肽，具有包含脯氨酸-赖氨酸-谷氨酸-赖氨酸(PKEK)的序列(SEQ ID No.1)；α熊果苷和/或舒替兰酶。这些组合物可经皮或皮下递送给受试者，以停止或逆转色素沉着过度。例如，本文中公开的组合物可以霜剂、液体或精华液的形式施用于受试者皮肤的受影响区域，所述霜剂、液体或精华液能够经皮递送有效量的活性成分到表皮、真皮和/或皮下组织，以引起皮肤美白。作为另外一种选择，本文中公开的用于减少或消除色素沉着过度的组合物可通过在受影响部位进行皮下注射而施用予受试者。
在一个方面中，色素稳定剂包含：肽，具有包含赖氨酸-脯氨酸-谷氨酸-赖氨酸的序列(SEQ ID NO：1)；及α熊果苷。在实施例中，色素稳定剂进一步包含舒替兰酶。
在一个方面中，色素稳定剂包含：肽，具有包含赖氨酸-脯氨酸-谷氨酸-赖氨酸的序列(SEQ ID NO：1)；及舒替兰酶。在实施例中，色素稳定剂进一步包含α熊果苷。
在一个方面中，色素稳定剂包含：肽，具有包含赖氨酸-脯氨酸-谷氨酸-赖氨酸的序列(SEQ ID NO：1)；α熊果苷；及舒替兰酶。
在一个方面中，稳定受试者皮肤的色素的方法包括向受试者局部或皮下施用治疗有效量的在本文中公开的色素稳定剂。例如，所述组合物可配制成精华液、霜剂、凝胶、液体或乳液。在实施例中，“稳定受试者皮肤的色素”可包括治疗色素沉着过度，美白受试者的皮肤，改善受试者皮肤的均匀性、色调和/或质地，和/或使受试者皮肤恢复到先前存在的色素沉着状态。
在一个实施例中，所述肽具有基本上由赖氨酸-脯氨酸-谷氨酸-赖氨酸组成的序列(SEQ ID NO：1)。在实施例中，所述肽是由赖氨酸-脯氨酸-谷氨酸-赖氨酸序列(SEQ IDNO：1)组成的四肽。
在一个实施例中，α熊果苷至少部分来源于熊果属中的植物。例如，所述熊果属中的所述植物可为熊果树(A.uva-ursi)。
在一个实施例中，肽以0.25wt％-5wt％之间的浓度存在，α熊果苷以2wt％-8wt％之间的浓度存在，且/或舒替兰酶以0.25wt％-2wt％之间的浓度存在。在实施例中，肽以0.25wt％-3wt％之间、或0.35wt％-2wt％之间、或0.4wt％-1.5wt％之间、或0.45wt％-1wt％之间、或0.5wt％-0.75wt％之间的浓度存在。在实施例中，α熊果苷以3wt％-6wt％之间、或3.5wt％-5.5wt％之间、或4wt％-5wt％之间的浓度存在。在实施例中，舒替兰酶以0.30wt％-1.75wt％之间、或0.35wt％-1.5wt％之间、或0.4wt％-1.25wt％之间、或0.45wt％-1wt％之间、或0.5wt％-0.75wt％之间的浓度存在。
在一个实施例中，色素稳定剂包含抗微生物剂、抗菌剂和/或抗真菌剂。
在一个实施例中，色素稳定剂包含曲霉发酵产物。
在一个实施例中，色素稳定剂包含粗糙帽果提取物。
在一个实施例中，色素稳定剂包含选自由角叉藻提取物、库拉索芦荟提取物、温州蜜柑皮提取物、光果甘草提取物、抗坏血酸甲基硅烷醇果胶酸酯、龙头竹提取物、蘑菇提取物及其组合组成的群组中的附加成分。
在一个实施例中，色素稳定剂包含选自由β-胡萝卜素及水解酵母提取物组成的群组中的一种或多种成分。
在一个实施例中，色素稳定剂包含一种或多种载体、赋形剂、防腐剂和/或稀释剂。
在一个实施例中，稳定受试者皮肤色素的方法包括每天两次、每天一次、每隔一天、每周一次或每月一次局部施用色素稳定剂。在实施例中，稳定受试者皮肤色素的方法包括每天两次、每天一次、每隔一天、每周一次或每月一次皮下施用色素稳定剂。
附图说明
无
具体实施方式
大体来说，本文中所使用的用语及短语具有其领域公认的含义，所述含义可通过参考标准文本、期刊参考文献及所属领域中的技术人员已知的上下文来找到。提供以下定义是为了阐明其在本说明书的上下文中的具体用途。
“氨基酸”是蛋白质的分子构建砌块(molecular building block)。“氨基酸残基”是蛋白质链或肽的最简单的离散单元或单体。
“舒替兰酶”是来源于细菌枯草芽孢杆菌的丝氨酸蛋白酶(即，酶)。
“α熊果苷”是4-氢醌-α-D-吡喃葡萄糖苷。
“曲霉发酵产物”是从曲霉属真菌的发酵中获得的提取物。
肽合成方法
一种生产肽的方法涉及化学合成。此可使用所属领域中的技术人员众所周知的固相方法来完成(参见例如约翰·莫罗·斯图尔特(Stewart,J.M.)&詹尼斯·达利亚·杨(Young，J.D.)的“固相肽合成(Solid Phase Peptide Synthesis)”，皮尔斯化学公司(Pierce Chemical Co.)，罗克福德，伊利诺伊州1984；梅里菲尔德(Merrifield)，《美国化学协会期刊(Journal of the American Chemical Society，J.Am.Chem.Soc.)》85:21491964；霍顿(Houghten)《美国国家科学院院刊(Proceedings of the National Academy ofSciences of the United States of America，Proc.Natl.Acad.Sci.USA)》82:51321985；以及美国专利第4,105,603号；第3,972,859号；第3,842,067号；以及第3,862,925号)。
固相合成通过将受保护的氨基酸偶联到合适的树脂(例如，氯甲基化聚苯乙烯树脂)从推定肽的羧基末端开始。在用例如二氯甲烷中的三氟乙酸(trifluoroacetic acid，TFA)移除α-氨基保护基团并在例如TEA中中和后，加入合成中的下一个α-氨基及侧链受保护的氨基酸。剩余的α-氨基及必要时侧链受保护的氨基酸然后通过缩合以所需的顺序依次偶联，以获得连接到树脂的中间化合物。作为另外一种选择，在将肽添加到生长的固相多肽链之前，一些氨基酸可彼此偶联形成肽。
两个氨基酸、或者一个氨基酸与一个肽或者一个肽与一个肽之间的缩合可根据例如叠氮化物方法、混合酸酐方法、N,N’-二环己基碳二亚胺(N,N'-dicyclohexylcarbodiimide，DCC)或N,N’-二异丙基碳二亚胺(N,N'-diisopropylcarbodiimide，DIPC)方法、活性酯方法(对硝基苯酯方法)、BOP苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐方法、N-羟基琥珀酸酰亚胺酯方法等惯常的缩合方法以及伍德沃德试剂K方法(Woodward reagent K method)施行。
肽的化学合成常见的是用合适的保护基团保护氨基酸的任何反应性侧链基团。最终，这些保护基团在所需的多肽链已被依序组装后被移除。同样常见的是保护氨基酸或片段上的α-氨基，同时所述实体在羧基处反应，随后选择性移除α-氨基保护基团，以允许随后的反应在所述位置发生。因此，在多肽合成中通常产生一种中间化合物，所述中间化合物含有位于肽链中所需序列中的每个氨基酸残基，这些残基中的各种残基附接有侧链保护基团。然后通常实质上同时移除这些保护基团，以便在从树脂中移除后生产所需的所得产物。
用于保护α-及ε-氨基侧链基团的合适保护基团由以下举例说明：苄氧羰基(CBZ)、异烟酰氧羰基(iNOC)、O-氯苄氧羰基(2-Cl-CBZ)、对-硝基苄氧羰基Z(NO2)、对-甲氧基苄氧羰基Z(OMe)、叔丁氧羰基(BOC)、叔戊基氧羰基(AOC)、异冰片氧羰基、金刚烷基氧羰基、2-(4-联苯)-2-丙氧羰基(BPOC)、9-芴基甲氧羰基(FMOC)、甲磺酰乙氧羰基(Msc)、三氟乙酰基、邻苯二酰、甲酰、2-硝基苯磺酸苯基(NPS)、二苯基硫膦基(Ppt)、二甲基硫膦基(Mpt)等。
羧基官能基的保护基团由以下举例说明：苄基酯(OBzl)、环己基酯(Chx)、4-硝基苄基酯(ONb)、叔丁基酯(OtBu)、4-吡啶基甲基酯(OPic)等。通常期望具有除氨基及羧基以外的官能基的特定氨基酸(例如，精氨酸、半胱氨酸及丝氨酸)被合适的保护基团保护。例如，精氨酸的胍基可用硝基、对甲苯磺酰基、苄氧羰基、金刚烷氧羰基、对甲氧基苯磺酰基、4-甲氧基-2,6-二甲基苯磺酰基(Mds)、1,3,5-三甲基苯磺酰基(Mts)等保护。半胱氨酸的巯基可用对甲氧基苄基、三苯基甲基、乙酰氨基甲基乙基甲氨酰、4-甲基苄基、2,4,6-三甲基-苄基(Tmb)等保护，且丝氨酸的羟基可用苄基、叔丁基、乙酰基、四氢吡喃基等保护。
在完成所需的氨基酸序列后，通过用例如液体HF及一种或多种含硫清除剂等试剂进行处理而从树脂载体上移除中间肽，此不仅从树脂切割肽，而且切割所有剩余的侧链保护基团。在HF切割后，用乙醚洗涤肽残留物，并通过用含水乙腈及乙酸进行洗涤而从树脂中进行提取。
氨基酸取代
蛋白质及肽化学的一个公认原则是，在不改变蛋白质或肽的构象或功能的情况下，可经常在蛋白质或肽中进行被称为“保守”氨基酸取代的某些氨基酸取代。保守取代可用于本文中所公开的蛋白质、肽或类似物的合成。因此，具有保守氨基酸取代的肽在本发明的范围内。此种变化包括用异亮氨酸(I)、缬氨酸(V)及亮氨酸(L)中的任意一者取代这些氨基酸中的任意另一者；用天冬氨酸(D)取代谷氨酸(E)，反之亦然；用谷氨酰胺(O)取代天冬酰胺(N)，反之亦然；以及用丝氨酸(S)取代苏氨酸(T)，反之亦然。上述取代并不是仅有的可被视为“保守”的氨基酸取代。依据特定氨基酸的环境，其他取代也可被视为保守的。举例来说，甘氨酸(G)与丙氨酸(A)可经常互换，丙氨酸与缬氨酸也可经常互换。相对疏水的甲硫氨酸(M)可经常与亮氨酸及异亮氨酸互换，且有时也可与缬氨酸互换。赖氨酸(K)及精氨酸(R)经常在氨基酸残基的显著特征是其电荷且这两个氨基酸残基的不同pK不显著的位置互换。当半胱氨酸(C)形成二硫键的能力是非期望的或不被需要时，半胱氨酸可经常被丝氨酸(S)替换。还有其他变化在特定环境下也可被视为“保守的”。
药物组合物
概括来说，本发明的药物组合物包含治疗有效量的肽(具有包括脯氨酸-赖氨酸-谷氨酸-赖氨酸的序列(SEQ ID NO：1))、α熊果苷和/或舒替兰酶、以及药学上可接受的载体、赋形剂或稀释剂。
治疗有效量可由所属领域中的普通技术人员参考本文中所阐述的剂量来确定。
所属领域中已知的常规药学上可接受的载体可包括醇(例如，乙醇)、血清蛋白、胆固醇、人血清白蛋白、脂质体、缓冲液(例如磷酸盐、水、无菌盐水或其他盐)、电解质、甘油、羟甲基纤维素、丙二醇、聚乙二醇、聚氧乙烯山梨聚糖、其他表面活性剂、植物油及常规抗菌剂或抗真菌剂(例如对羟基苯甲酸酯、氯代丁醇、苯酚、山梨酸等)。本发明的范围内的药学上可接受的载体满足无菌性、等渗性、稳定性及无热原性的工业标准。
活性成分通常与生理上可耐受且与活性成分相容的稀释剂或赋形剂混合。适合的稀释剂及赋形剂是例如水、盐水、葡萄糖、甘油、或类似物及其组合。另外，如果需要，则组合物可含有少量的辅助物质，例如润湿剂或乳化剂、稳定剂或pH缓冲剂等。关于前述内容的更详细说明，参见标准药物文本，例如《雷明顿药物科学(Remington's PharmaceuticalSciences)》，麦克出版公司(Mack Publishing Co.)，伊斯顿，宾夕法尼亚州(1970)。
使用及施用方法
本发明的化合物被证明会减少或消除皮肤色素沉着过度。根据本发明的皮肤美白制剂可通过一定数目的途径施用，所述途径包括但不限于局部施用及皮下施用。
所属领域中的普通技术人员可依据疾病的临床严重程度、患者的年龄、性别及体重、患者暴露于可能影响治疗过程的条件(例如，日光)、潜在系统性问题(例如糖尿病、循环受损及免疫低下状态)的存在与否以及所属领域中一般理解的其他药物代谢动力学因素(例如肝及肾代谢)来确定要施用的剂量。各种大小及物种的动物以及人基于mg/m3表面积的剂量的相互关系由E.J.弗赖雷克(E.J.Freireich)等人的“抗癌剂在小鼠、大鼠、仓鼠；狗、猴子及人中毒性的定量比较(Quantitative Comparison of Toxicity of AnticancerAgents in Mouse,Rat,Hamster；Dog,Monkey and Man)”，《癌症化疗报告(CancerChemother.Rep.)》50:219-244(1966)阐述。可调整剂量方案以优化治疗反应。剂量可每天分开施用，或者也可依据治疗情况按比例减少剂量。
根据本发明的方法可用于治疗人或者在社会或经济上重要的动物物种。根据本发明的方法不限于用于人。
本发明通过以下实例进行例示。这些实例仅用于例示目的，且不旨在限制本发明。
实例1：色素稳定剂
此实例描述了包含表1所示成分的色素稳定剂。
表1.色素稳定剂成分.
实例2：制作色素稳定剂的方法
制作色素稳定剂的示例性方法包含在单一容器中组合所有成分，并用桨、搅拌器或旋转螺杆以中高速混合5分钟到1小时之间，直到形成实质上均匀的混合物。
关于并入供参考及变型的声明
本申请通篇引用的所有参考文献(例如包括已发布或授权的专利或等效物在内的专利文件；专利申请公开；以及非专利文献文件或其他源材料)如同单个并入供参考一般特此全文并入本文供参考。
本文中已采用的用语及表达被用作说明性用语而非限制性用语，且在使用此种用语及表达时不旨在排除所示出及所阐述的特征或其部分的任何等效物，但应认识到，在所主张的本发明的范围内可进行各种修改。因此，应理解，尽管本发明已经通过优选实施例、示例性实施例及可选特征进行了具体公开，然而所属领域中的技术人员可诉诸于本文中所公开的概念的修改及变型，且此种修改及变型被视为在如由随附权利要求书所界定的本发明的范围内。本文中所提供的具体实施例是本发明的有用实施例的实例，且对于所属领域中的技术人员来说将显而易见，可使用本说明中所述的器件、器件组件及方法步骤的大量变型来施行本发明。如对于所属领域中的技术人员来说将显而易见，对本发明方法及器件有用的方法及器件可包括大量可选的组合物以及处理元件及步骤。
当本文中公开一组取代基时，应理解所述组的所有单个成员及所有子组是分开公开的。当本文中使用马库什组(Markush group)或其他分组时，所述组的所有单个成员以及所述组的所有可能的组合及子组合都旨在单个地包括在本公开中。
必须注意，除非上下文另外清楚地指明，否则如本文中及随附权利要求书中所使用的单数形式“一”及“所述”包括复数指称。因此，举例来说，提及“肽”包括所属领域中的技术人员已知的多个此种肽及其等效物，等等。同样，用语“一”、“一个或多个”及“至少一个”在本文中可互换使用。还应注意，用语“包括”、“包含”及“具有”可互换使用。表达“如权利要求XX-YY中任一项所述的”(其中XX及YY指代权利要求号码)旨在以替代形式提供多项从属权利要求，且在一些实施例中可与表达“如在权利要求XX-YY中任意一项中所述的”互换。
除非另外定义，否则本文中所使用的所有技术用语及科学用语均具有与本发明所属领域中的普通技术人员所通常理解的含义相同的含义。尽管在本发明的实践或测试中可使用相似于或等效于本文中所阐述的方法及材料的任何方法及材料，然而阐述优选的方法及材料。本文中的任何内容均不应被解释为承认本发明无权凭借先前的发明先于此种公开。
每当说明书中给定范围(例如整数范围、温度范围、时间范围、组合物范围或浓度范围)时，所有中间范围及子范围以及包括在给定范围中的所有单个值均旨在包括在本公开中。本文中所使用的范围具体包括作为所述范围的端点值提供的值。本文中所使用的范围具体包括所述范围的所有整数值。举例来说，1到100的范围具体包括端点值1及100。应理解，本文中的说明中所包括的范围或子范围中的任何子范围或单个值均可从本文中的权利要求书排除。
本文中所使用的“包括”与“包括”、“含有”或“其特征在于”同义且可与“包括”、“含有”或“其特征在于”互换使用，且是包含性的或开放式的，且不排除附加的、未陈述的元件或方法步骤。本文中所使用的“由……组成”排除权利要求要素中未指定的任何要素、步骤或成分。本文中所使用的“本质上由……组成”不排除不实质上影响权利要求的基本及新颖特性的材料或步骤。在本文中的每一例子中，用语“包括”、“本质上由……组成”及“由……组成”中的任一者可利用另外两个用语中的任一者来替换。本文中例示性地阐述的本发明可在不存在本文中所未具体公开的任意一个或多个要素、一个或多个限制的情况下以适合方式实践。
材料及方法的所有领域已知的功能等效物旨在包括在本公开中。已采用的用语及表达被用作说明性用语而非限制性用语，且在使用此种用语及表达时不旨在排除所示出及所阐述的特征或其部分的任何等效物，但应认识到，在所主张的本发明的范围内可进行各种修改。因此，应理解，尽管本发明已经通过优选实施例及可选特征进行了具体公开，然而所属领域中的技术人员可诉诸于本文中所公开的概念的修改及变型，且此种修改及变型被视为在如由随附权利要求书所界定的本发明的范围内。
SEQUENCE LISTING
<110> C·扎维拉
林明盛
<120> 色素稳定剂
<130> 35-20 US
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic peptide
<400> 1
Pro Lys Glu Lys
1
Claims (20)
1.一种色素稳定剂，其特征在于，包含：
肽，具有赖氨酸-脯氨酸-谷氨酸-赖氨酸序列(SEQ ID No.1)；及α熊果苷。
2.如权利要求1所述的色素稳定剂，其特征在于，所述α熊果苷至少部分来源于熊果属中的植物。
3.如权利要求2所述的色素稳定剂，其特征在于，所述熊果属中的植物是熊果树。
4.如权利要求1所述的色素稳定剂，其特征在于，所述肽以0.25wt％-5wt％之间的浓度存在，并且所述α熊果苷以2wt％-8wt％之间的浓度存在。
5.如权利要求1所述的色素稳定剂，其特征在于，进一步包含舒替兰酶。
6.如权利要求5所述的色素稳定剂，其特征在于，所述舒替兰酶以0.25wt％-2wt％之间的浓度存在。
7.如权利要求1所述的色素稳定剂，其特征在于，进一步包含曲霉发酵产物。
8.如权利要求1所述的色素稳定剂，其特征在于，进一步包含粗糙帽果提取物。
9.如权利要求1所述的色素稳定剂，其特征在于，进一步包含附加成分，所述附加成分选自：角叉藻提取物、库拉索芦荟提取物、温州蜜柑皮提取物、光果甘草提取物、抗坏血酸甲基硅烷醇果胶酸酯、龙头竹提取物、蘑菇提取物或其组合组成的群组。
10.如权利要求1所述的色素稳定剂，其特征在于，进一步包含选自：β-胡萝卜素及水解酵母提取物组成的群组中的一种或多种成分。
11.一种稳定受试者皮肤的色素的方法，其特征在于，所述方法包含向所述受试者局部施用治疗有效量的如权利要求1所述的色素稳定剂。
12.一种色素稳定剂，其特征在于，包含：
肽，具有赖氨酸-脯氨酸-谷氨酸-赖氨酸序列(SEQ ID No.1)；及
舒替兰酶。
13.如权利要求12所述的色素稳定剂，其特征在于，所述肽以0.25wt％-5wt％之间的浓度存在，并且所述舒替兰酶以0.25wt％-2wt％之间的浓度存在。
14.如权利要求12所述的色素稳定剂，其特征在于，进一步包含α熊果苷。
15.如权利要求14所述的色素稳定剂，其特征在于，所述α熊果苷至少部分来源于熊果属中的植物。
16.如权利要求16所述的色素稳定剂，其特征在于，所述熊果属中的植物是熊果树。
17.如权利要求12所述的色素稳定剂，其特征在于，进一步包含曲霉发酵产物。
18.如权利要求12所述的色素稳定剂，其特征在于，进一步包含粗糙帽果提取物。
19.如权利要求12所述的色素稳定剂，其特征在于，进一步包含附加成分，所述附加成分选自：角叉藻提取物、库拉索芦荟提取物、温州蜜柑皮提取物、光果甘草提取物、抗坏血酸甲基硅烷醇果胶酸酯、龙头竹提取物、蘑菇提取物或其组合组成的群组。
20.如权利要求12所述的色素稳定剂，其特征在于，进一步包含选自：β-胡萝卜素及水解酵母提取物组成的群组中的一种或多种成分。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/070,140 | 2020-10-14 | ||
| US17/070,140 US20220110852A1 (en) | 2020-10-14 | 2020-10-14 | Pigment Stabilizers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114344186A true CN114344186A (zh) | 2022-04-15 |
Family
ID=78179241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111199733.9A Pending CN114344186A (zh) | 2020-10-14 | 2021-10-14 | 色素稳定剂 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220110852A1 (zh) |
| EP (1) | EP3988080A1 (zh) |
| KR (1) | KR20220049474A (zh) |
| CN (1) | CN114344186A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060188559A1 (en) * | 2005-02-18 | 2006-08-24 | E. T. Browne Drug Co. | Topical cosmetic compositions comprising alpha arbutin |
| CN102573776A (zh) * | 2009-11-17 | 2012-07-11 | 赢创高施米特有限公司 | 用于皮肤增亮的四肽 |
| CN102697702A (zh) * | 2012-06-08 | 2012-10-03 | 钟春燕 | 一种美白保湿修复体膜及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (zh) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US5958437A (en) * | 1997-06-06 | 1999-09-28 | Geneda Corporation | Dermatological healing kit, components therefor, and process for making |
| EP1318825A2 (de) * | 2000-07-26 | 2003-06-18 | Vitaplant AG | Piper methysticum pflanzenextrakt |
| WO2006004787A1 (en) * | 2004-06-28 | 2006-01-12 | Procyte Corporation | Methods and compositions for preventing and treating hyperpigmentation of skin |
| WO2006136003A1 (en) * | 2005-04-20 | 2006-12-28 | Laboratoires Mauves Inc. | Organic silicic acids complex for therapeutic and cosmetic applications |
| EP2740484A1 (en) * | 2012-12-05 | 2014-06-11 | Lipotec, S.A. | Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions |
| WO2017100421A1 (en) * | 2015-12-10 | 2017-06-15 | Lubrizol Advanced Materials, Inc. | Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes |
| JP7227903B2 (ja) * | 2016-11-30 | 2023-02-22 | ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド | 皮膚、毛髪、爪および／もしくは粘膜の処置ならびに／またはケアに有用な化合物 |
-
2020
- 2020-10-14 US US17/070,140 patent/US20220110852A1/en active Pending
-
2021
- 2021-10-13 KR KR1020210135650A patent/KR20220049474A/ko not_active Application Discontinuation
- 2021-10-13 EP EP21202366.7A patent/EP3988080A1/en active Pending
- 2021-10-14 CN CN202111199733.9A patent/CN114344186A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060188559A1 (en) * | 2005-02-18 | 2006-08-24 | E. T. Browne Drug Co. | Topical cosmetic compositions comprising alpha arbutin |
| CN102573776A (zh) * | 2009-11-17 | 2012-07-11 | 赢创高施米特有限公司 | 用于皮肤增亮的四肽 |
| CN102697702A (zh) * | 2012-06-08 | 2012-10-03 | 钟春燕 | 一种美白保湿修复体膜及制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220049474A (ko) | 2022-04-21 |
| US20220110852A1 (en) | 2022-04-14 |
| EP3988080A1 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331305B2 (en) | Peptides for skin rejuvenation and methods of using the same | |
| US20220183950A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| KR101870898B1 (ko) | 갈릭산이 결합된 펩타이드 유도체 및 그를 포함하는 항노화 피부 외용제 조성물 | |
| KR20110092288A (ko) | 인터루킨-1 및 펩티드를 함유하는 조성물 | |
| KR101261065B1 (ko) | 눈밑 윤곽 아래에 형성된 지방의 감소 또는 제거를 위한합성 펩티드 및 화장품 또는 피부약 조성물에서의 이것의용도 | |
| JPH0543442A (ja) | 皮膚化粧料 | |
| US20060293227A1 (en) | Cosmetic compositions and methods using transforming growth factor-beta mimics | |
| CN114344186A (zh) | 色素稳定剂 | |
| KR20150110332A (ko) | 필러의 효능 유지용 조성물 | |
| US20180344798A1 (en) | Topically active peptides for treating cosmetic and dermatological conditions | |
| EP2858721B1 (en) | Stable pexiganan formulation | |
| US11596665B2 (en) | Skin lightening formulations | |
| US11951203B2 (en) | Deep wrinkle vanishing compositions | |
| WO2006106633A1 (ja) | 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤 | |
| EP3366273A1 (en) | Moisturizer and cosmetic containing same | |
| EP3977978A1 (en) | Intense skin hydration systems and methods | |
| WO2024038345A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| CN113121643A (zh) | 用于黑色素聚合及发色变黑的多肽、方法及组合物 | |
| KR102084521B1 (ko) | 여드름 예방 및 개선용 조성물 | |
| JPH05213732A (ja) | 皮膚化粧料 | |
| JPH03123716A (ja) | メラノサイト刺激ホルモン拮抗剤および該拮抗剤を含有する皮膚外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220415 |
|
| WD01 | Invention patent application deemed withdrawn after publication |